Shortage reports
Actual shortage:
257 (7%)
Anticipated shortage:
3 (0%)
Avoided shortage:
11 (0%)
Resolved:
3300 (92%)
3571
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
32 (11%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-09-17 | 2021-10-25 | 145822 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2024-02-23 | 2024-03-01 | 220444 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-05-03 | 2024-06-21 | 227082 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2019-07-31 | 2019-08-02 | 90341 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2019-03-27 | 2019-03-29 | 79574 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-01-19 | 2024-02-09 | 216672 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-09-20 | 2024-11-08 | 238245 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-06-11 | 2021-08-06 | 140772 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2019-12-05 | 2020-02-18 | 100265 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2020-05-13 | 2020-05-19 | 114937 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2024-05-24 | 2024-06-21 | 228807 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2022-04-08 | 2022-08-24 | 158348 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2025-09-11 | 2025-09-19 | 267023 |
| APO-CEFPROZIL | 250MG | TABLET | Resolved | 2017-03-10 | 2017-10-03 | 71 |
| APO-CEFPROZIL | 500MG | TABLET | Resolved | 2017-03-10 | 2017-10-03 | 74 |
| APO-CEFPROZIL | 500MG | TABLET | Actual shortage | 2018-09-28 | 2018-09-28 | 62607 |
| APO-CEFPROZIL | Resolved | 2018-09-28 | 2019-05-24 | 62618 | ||
| APO-CEFPROZIL | Resolved | 2018-09-28 | 2019-06-12 | 62614 | ||
| APO-CEFUROXIME | 250MG | TABLET | Resolved | 2018-02-05 | 2018-04-14 | 38505 |
| APO-CEFUROXIME | 250MG | TABLET | Resolved | 2023-02-02 | 2023-02-09 | 183495 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
| APO-HYDROMORPHONE CR | 4.5MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110974 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |